ATHOS
VC Fund
ATHOS is a well-known single-family office dedicated to advancing cutting-edge technologies and creating revolutionary businesses by making value-based, entrepreneurial investments.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries ATHOS invests in
BiotechnologyHealth CareMedical DevicePharmaceuticalMedical
Stages ATHOS invests in
Series BSeries APrivate EquitySecondary Market
Countries ATHOS invests in
GermanySwitzerlandBelgiumDenmark
Investment Focus
Industry
- Biotechnology 4 (50%)
- Health Care 3 (38%)
- Medical Device 2 (25%)
- Pharmaceutical 2 (25%)
- Medical 1 (13%)
Stage
- Series B 3 (38%)
- Series A 2 (25%)
- Private Equity 1 (13%)
- Secondary Market 1 (13%)
Country
- Germany 2 (25%)
- Switzerland 2 (25%)
- Belgium 1 (13%)
- Denmark 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Bactolife
|
Bactolife helps in developing innovative solutions meeting the global need for reducing antimicrobial resistance. Its products are based on minimizing the risk of disease through reduction of virulence, making pathogens unable to establish an active infection. | $35.2M / Series B / Jan 06, 2026 | |
MRM Health NV
|
MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications. | $64.1M / Series B / Sep 04, 2025 | |
HAYA Therapeutics
|
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $65M / Series A / May 08, 2025 | |
Aignostics
|
Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis. | $34M / Series B / Oct 29, 2024 | |
Isotopen Technologien München
|
ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries haveestablished GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITM’s isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company.Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. | $204.8M / Private Equity / Jun 06, 2024 | |
|
Bactolife
|
Bactolife helps in developing innovative solutions meeting the global need for reducing antimicrobial resistance. Its products are based on minimizing the risk of disease through reduction of virulence, making pathogens unable to establish an active infection. | $32.9M / Series A / Aug 08, 2023 | |
|
Isotopen Technologien München
|
ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries haveestablished GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITM’s isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company.Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. | $273.1M / Private Equity / Jun 05, 2023 | |
SHL Medical
|
SHL Medical designs develops and manufactures advanced drug delivery systems such as auto-injectors and pen injectors, they understand the importance of adhering to strict regulations, uncompromised quality standards, and overall world-class professionalism. | Secondary Market / Dec 09, 2022 |
Co-Investors
BIOCODEX
2 deals together
BlackRock
2 deals together
Carbyne
2 deals together
EQT
2 deals together
Novo Holdings
2 deals together
Qatar Investment Authority
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does ATHOS invest in?
ATHOS invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did ATHOS last invest?
The most recent investment recorded for ATHOS closed in Jan 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
